AE costs
A cumulative cohort model was developed to estimate the five-year costs associated with introducing everolimus to the Kazakhstan healthcare system. In order to do so, two alternative scenarios were compared: (i) An existing state of affairs, with current market share being used to estimate the numbers of patients receiving different treatments, and (ii) an 'intervention' scenario, where everolimus is introduced to the market and assumed to replace a proportion of existing treatments. These have been named as without everolimus and with everolimus respectively. The market share used within the model are shown in Table 1 below.
Progression-free survival (PFS) and overall survival (OS) data were taken from the trial and extrapolated. The background costs of the pre-progressed and postprogressed health states, drug costs and costs associated with adverse events were included in the model. The budget impact was estimated for 2014 to 2018.
The five-year results from the budget impact analysis are shown in Figure 1 . These demonstrate that the introduction of everolimus leads to a 12% increase in drug costs, a 2% reduction in pre-progression health state costs, a 1% increase in post-progression health state costs and a 2% reduction in adverse event costs. The net result is only a modest increase in total costs; a 2.69% increase of T201 million, from T7.5 billion to T7.7 billion over a period of five years. The full results can be found in Figure 1 below.
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Figure 1: Budget impact analysis results
Results
Conclusions
The analysis estimated that, if everolimus were to be introduced to the Kazakhstan healthcare market for the treatment of ER+ HER2-advanced breast cancer, there would be minimal impact upon overall healthcare expenditure. An increase in drug acquisitions costs was almost exactly offset by a reduction in other healthcare costs due to improved management of the disease. 3 . Metastatic breast cancer is the presence of disease at distant sites. It is estimated that the total number of patients with breast cancer will be more than 27,000 in Kazakhstan in 2014, of which around 8% will develop metastatic disease 4 .
Contact Us
The effectiveness of everolimus (in combination with exemestane) has been demonstrated against exemestane alone in the BOLERO-2 trial. The BOLERO-2 trial 5 was a randomised, double-blind, phase III study of everolimus plus exemestane versus exemestane plus placebo, which has been conducted in 189 centres in 24 countries. The trial participants were women with HER2-negative, ER+ advanced or metastatic breast cancer whose disease had recurred or progressed following prior treatment with nonsteroidal aromatase inhibitors.
The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2-negative advanced and metastatic breast cancer in postmenopausal women. 
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